CapsoVision Inc (CV) Stock News

The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.

Block & Leviton is investigating CVRx, Inc., Papa John's International, and HubSpot for potential securities fraud. CVRx cut its revenue guidance citing sales force challenges and reimbursement issues, while HubSpot experienced a 25% share price decline. Investors who have suffered losses are encouraged to contact the firm.

Johnson Fistel is investigating CVRx, Inc. for potential securities law violations following the company's August 6, 2026 revenue guidance cut from $63-67 million to $58-60 million. The downward revision was attributed to sales force execution challenges, high employee turnover, slower productivity ramps, and reimbursement issues with a major Medicare Advantage payer. CVRx also disclosed receiving a Department of Justice civil investigative demand regarding sales and marketing practices.

CVG reported Q2 2026 revenues of $195.2 million, up 13.5% year-over-year, with gross margin expansion of 140 basis points. Despite a net loss of $8.7 million ($0.25 per share), adjusted EBITDA reached $5.4 million. The company raised its full-year 2026 revenue guidance to $725-$755 million and adjusted EBITDA guidance to $26-$31 million, citing strong performance across all three business segments and improving market conditions.

Novo Nordisk announced that ziltivekimab failed to meet its primary endpoint in the ZEUS phase 3 trial, showing no significant reduction in major adverse cardiovascular events (MACE) despite achieving the expected biological effect of IL-6 pathway inhibition. The drug demonstrated a hazard ratio of 0.99 versus placebo in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The company will take a non-cash impairment charge in Q3 2026 but maintains its 2026 profit outlook and plans to continue two additional cardiovascular trials (HERMES and ARTEMIS) expected to report in H1 2027.

CVB Financial Corp. announced the appointment of Michael J. Maddox as Director of both CVBF and Citizens Business Bank, increasing board size from 10 to 11 members. Maddox brings over 20 years of banking experience, including previous roles as CEO of CrossFirst Bankshares and leadership positions at First Busey Corporation.

Grabar Law Office has launched multiple shareholder investigations against Commvault Systems, GPGI Inc., Hub Group, and Zillow Group, alleging that officers and directors breached fiduciary duties through materially false statements and misleading disclosures. Allegations include overstated ARR growth projections, misrepresented acquisition values, financial statement misstatements, and undisclosed antitrust risks. Long-term shareholders who purchased shares before specified dates and still hold them may seek corporate reforms and compensation at no cost.

Prenetics Global Limited announced a $1 billion growth financing deal with General Catalyst's Customer Value Fund to accelerate IM8's marketing spend. The company raised its full-year 2026 revenue guidance to $210-220 million (from $190-210 million) and projects $300 million annualized run-rate by year-end 2026 and $400+ million in full-year 2027 revenue. IM8, co-founded by David Beckham, has become the fastest-growing premium supplement brand ever, delivering 200,000 servings daily across 43 countries with strong unit economics ($1.44 gross profit return per $1 acquisition spend).

The MARS2 Multimodal Reasoning Competition has been officially launched, sponsored by Tec-Do and MiniMax. The competition features a $100,000 prize pool and three tracks (MAC, VTG, MDC) designed to test multimodal AI models in complex, real-world scenarios. The event will be held September 8-9, 2026 in Malmö, Sweden, alongside the ECCV 2026 conference, with paper submissions due August 1, 2026.

Rosen Law Firm announces important deadlines for securities class action lawsuits against Commvault Systems, Inc. (CVLT) and Veritone, Inc. (VERI). Investors who purchased securities during specified periods and suffered losses exceeding $100,000 are encouraged to secure legal counsel. The CVLT lawsuit alleges the company made false statements regarding annual recurring revenue (ARR) growth, while the VERI lawsuit details are partially mentioned. Key deadlines are July 17, 2026 for CVLT and July 20, 2026 for VERI.

Rosen Law Firm is encouraging investors with significant losses to join securities class action lawsuits against Commvault Systems, Calix, Inc., and The Ensign Group. The firm is seeking lead plaintiffs before the July 17, 2026 deadline. The Commvault lawsuit alleges the company made false statements regarding ARR growth guidance while concealing material adverse facts.

Rosen Law Firm has issued deadline notices for securities class action lawsuits against Commvault Systems, AeroVironment, and Calix. The firm is seeking lead plaintiffs with losses exceeding $100K before the July 17, 2026 deadline. The Commvault case alleges the company made false statements regarding ARR growth guidance while concealing material adverse facts.

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.

Mizuho analyst Ann Hynes raised her CVS Health price target to $115 per share, implying 13% upside from current levels. The article suggests CVS could see even greater upside potential, potentially reaching $150 per share if it achieves a valuation multiple similar to UnitedHealth Group, given its transformation into a diversified healthcare services company and expected double-digit earnings growth.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies. Phreesia Inc. faces allegations of misrepresenting growth projections, Sportradar Group AG is accused of working with black-market gambling operators while claiming compliance, Commvault Systems Inc. allegedly failed to properly account for sales type impacts on ARR growth, and Veritone Inc. is charged with revenue misclassification and deficient internal controls. Investors have until mid-July 2026 to file lead plaintiff motions.

XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Phreesia Inc., Sportradar Group AG, Commvault Systems Inc., and Veritone Inc. Investors have until mid-July 2026 to file lead plaintiff motions. The complaints allege various forms of misrepresentation including false growth projections, undisclosed compliance violations, misleading revenue guidance, and accounting irregularities.

Rosen Law Firm is soliciting investors who purchased securities of Commvault Systems (CVLT) between April 29, 2025 and January 26, 2026 to join a class action lawsuit. The lawsuit alleges that Commvault provided false and misleading statements regarding ARR growth guidance while concealing material adverse facts. The lead plaintiff deadline is July 17, 2026. Similar class action notices are being issued for Calix, Inc. and FLOW cryptocurrency.

Chevron reported Q1 2026 earnings that fell 35% year-over-year due to hedging timing headwinds, but underlying fundamentals were strong. The company increased U.S. production 24% following the Hess acquisition and returned $6 billion to shareholders through dividends and buybacks. While the company benefits from elevated oil prices driven by Middle East geopolitical tensions, investors should be cautious about buying based solely on current high oil prices, as sentiment-driven volatility could reverse if the conflict ends.

Chevron (CVX) is a highly leveraged bet on crude oil prices and geopolitical risk in the Strait of Hormuz. The stock has declined from $214.71 to $188 as oil prices fell 20% on ceasefire hopes between the U.S. and Iran. While CVX offers a fortress dividend with 39 years of consecutive growth and a reasonable 14x forward P/E multiple, its earnings are heavily dependent on oil prices remaining elevated. The stock faces a binary outcome: if the ceasefire holds, crude falls and CVX declines further; if talks collapse, crude spikes and CVX rallies significantly. Notable headwinds include Berkshire Hathaway's 35% stake reduction and insider selling.

Rosen Law Firm is encouraging investors who purchased securities of Commvault Systems, Calix, Inc., and Wise Group plc during specified periods to join class action lawsuits. The Commvault lawsuit alleges the company made materially false statements regarding ARR growth guidance and concealed material adverse facts. Lead plaintiff deadlines and contingency fee arrangements are available for eligible investors.

Rosen Law Firm is soliciting investors to join securities class action lawsuits against Commvault Systems, ChampionX Corporation, and Regencell Bioscience Holdings. The firm reminds investors of upcoming lead plaintiff deadlines and offers contingency-based legal representation. The lawsuits allege that defendants made materially false statements and concealed adverse facts regarding financial performance.

CVS Health's dividend is sustainable despite the company pausing annual increases. With Q1 2026 operating cash flow of $4.2 billion and expected annual cash flow of at least $9.5 billion, CVS comfortably covers its $3.39 billion projected dividend payout (representing just over 20% of cash flow). The company's 2.89% dividend yield significantly exceeds the S&P 500 average, making it an attractive income investment with minimal risk of elimination.

H1, an AI-powered healthcare platform for identifying and engaging physicians, secured a $40M investment led by CVS Health Ventures. The funding follows successful collaborations between the companies, including an AI model that improved healthcare provider directory accuracy. H1 serves 85% of top 20 pharma companies and 9 out of 10 top health plans, and is on track to achieve above Rule of 40 profitability metrics in 2026.

The iShares Morningstar Small-Cap Value ETF (ISCV) has outperformed the iShares S&P Mid-Cap 400 Value ETF (IJJ) over the past year with a 30.94% return versus 22.25%, driven by small-cap optimism around domestic growth and deregulation. However, ISCV carries higher volatility with a deeper maximum drawdown of 25.30% compared to IJJ's 22.70%. ISCV offers a lower expense ratio of 0.06% versus IJJ's 0.18%, making it attractive for cost-conscious investors, though IJJ provides greater stability and liquidity with its larger asset base.

Despite Brent crude oil rising 85% in 2026 due to Middle East geopolitical tensions, Occidental Petroleum, ExxonMobil, and Chevron benefited unevenly in Q1. Timing of the oil price spike (occurring mainly in March), regional exposure differences, and hedging activities created headwinds. Oxy beat expectations with $1.06 EPS vs. $0.59 expected, while Exxon earned $1.16 vs. $1.01 expected and Chevron earned $1.41 vs. $0.97 expected, but both faced significant hedging charges. Q2 expectations are substantially higher.

CVS Health stock has surged 24% over the past month following strong Q1 earnings that beat analyst expectations, with revenue up 6.2% to $100.4B and EPS up 62% to $2.30. The company raised full-year guidance and is benefiting from improved margins in its Aetna insurance segment and growth from Rite Aid store acquisitions. However, the company carries significant debt of $86.4B in long-term obligations, though it is gradually reducing overall leverage.

Rosen Law Firm has filed class action lawsuits against Commvault Systems, Inc. (CVLT) on behalf of investors who purchased securities between April 29, 2025 and January 26, 2026. The lawsuit alleges that Commvault provided materially false and misleading statements regarding ARR growth guidance while concealing material adverse facts. Investors have until July 17, 2026 to move the court to serve as lead plaintiff. Similar class action investigations are ongoing for PennyMac Financial Services and ChampionX Corporation.

CVD Equipment (NASDAQ:CVV) shares fell 17.66% in after-hours trading after reporting a steep 70.9% revenue decline to $1.8 million in Q1 2026, wider net losses, and continued pressure from geopolitical uncertainty and lower university funding. However, the company completed the sale of its SDC division generating $14.8 million in cash proceeds, improving its balance sheet with $23 million in cash and no long-term debt.